Inventor · disambiguated record
Xiangyong Liu
Also filed as: LIU XIANGYONG
4 granted patents·18 pending applications·7 citations·filing 2014–2023
63Inventor score
Top patents by PatentIndex Score
22 records- 0189US11365196B2FGFR inhibitor and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2018·Granted Jun 21, 2022·6 cites·33 claims
- 0271US10059688B2Protein tyrosine kinase modulators and methods of useBETTA PHARMACEUTICALS CO LTD·Filed 2017·Granted Aug 28, 2018·1 cites·19 claims
- 0360US2024352053A1Salt and crystal form of egfr inhibitor, and composition and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0460US2025051301A1Mutant idh1 and idh2 inhibitor and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 0560US2025223300A1Macrocyclic compound and pharmaceutical composition and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 0657US2025154149A1Pharmaceutical composition and method for preparing active ingredient compound thereofBETTA PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 0755US9783524B2Protein tyrosine kinase modulators and methods of useBETTA PHARMACEUTICALS CO LTD·Filed 2014·Granted Oct 10, 2017·0 cites·9 claims
- 0855US2024336594A1Six-membered aryl or heteroaryl amides, and composition and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0951US2023391779A1Bicyclic compounds, compositions and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 1050US2022227796A1Egfr inhibitors, compositions and methods there ofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 1150US2023133169A1Egfr inhibitor, composition, and method for preparation thereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 1250US2024174681A1Salt and crystalline forms of fgfr4 inhibitor and uses thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 1350US2023053342A1Imidazolidinone compound, preparation method therefor and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 1449US2023131025A1Quinolyl phosphine oxide compound, and composition and application thereofBETTA PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 1549US2022402948A1Egfr inhibitor, composition and preparation method thereforBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 1647US2022064196A1EGFR Inhibitors, Compositions and Methods ThereofBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 1745US2022259235A1EGFR Inhibitor, Composition, and Preparation Method ThereforBETTA PHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 1844US2021395256A1Tyrosine kinase inhibitors, compositions and methods there ofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 1943US12275737B2Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applicationsMERYX INC·Filed 2020·Granted Apr 15, 2025·0 cites·16 claims
- 2042US2022119411A1Immunomodulators, compositions and methods thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 2142US2022002307A1Fgfr4 inhibitor and use thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 2240US2021040118A1Immunomodulators, compositions and methods thereofBETTA PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xiangyong Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →